Novo Nordisk(US:NVO) 经济观察报·2025-09-10 13:21Core Viewpoint - Novo Nordisk is undergoing significant layoffs, with plans to cut approximately 9,000 jobs, representing about 11% of its global workforce, as part of a transformation strategy to streamline operations and focus on growth opportunities in diabetes and obesity treatment [2][3][4]. Group 1: Layoff Details - Novo Nordisk announced layoffs of around 9,000 employees, aiming to save 8 billion Danish kroner (approximately 8.94 billion RMB) annually by the end of 2026 [2]. - The layoffs are part of a broader transformation plan due to recent growth slowdowns, with the company adjusting its organizational structure to enhance decision-making speed [3][4]. - The company currently employs 78,400 people globally, with over half of the layoffs expected to come from its headquarters in Denmark [3]. Group 2: Financial Impact - Novo Nordisk has revised its 2025 operating profit growth forecast down to 4%-10%, from a previous estimate of 10%-16% [3]. - The transformation plan is expected to incur a one-time restructuring cost of 8 billion Danish kroner, which will negatively impact the operating profit growth forecast by approximately 6 percentage points [5]. Group 3: Market Context - The company has seen a slowdown in growth, particularly in key markets like the U.S. and China, where sales of its diabetes drug, semaglutide, have declined by about 11% in the first half of 2025 [4]. - Novo Nordisk's semaglutide generated $16.5 billion in revenue in the first half of 2025, surpassing the previous top-selling drug, K drug, which earned $15.2 billion [4].